CHARACTERIZATION OF CAMPTOTHECIN-RESISTANT CHINESE-HAMSTER LUNG-CELLS

被引:81
作者
CHANG, JY
DETHLEFSEN, LA
BARLEY, LR
ZHOU, BS
CHENG, YC
机构
[1] YALE UNIV,SCH MED,DEPT PHARMACOL,333 CEDAR ST,NEW HAVEN,CT 06510
[2] UNIV UTAH,HLTH SCI CTR,DEPT RADIOL,SALT LAKE CITY,UT 84132
关键词
D O I
10.1016/0006-2952(92)90325-D
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Three camptothecin-resistant sublines (V79r, IRS-1r and IRS-2r) of V79 cells and their irradiation-sensitive mutants, IRS-1 and IRS-2, were developed by stepwise, continuous exposure to camptothecin (CPT). The degree of resistance varied among these cells. Based on the biochemical characterizations of these resistant cell lines, the mechanisms which could be responsible for the resistance of CPT were proposed to be: (a) a decrease in the intracellular accumulation of CPT with or without alteration of DNA topoisomerase I, (b) a decrease in the amount of DNA topoisomerase I, or (c) a decrease in the sensitivity of DNA topoisomerase I to CPT. The resistant cells which exhibited down-regulation of DNA topoisomerase I were collaterally sensitive to etoposide (VP-16) and its analogue, 4'-demethy-4-beta-(4"-fluoroanilino)-4-desoxypodophyll?? otoxin, despite the fact that there were equal amounts of DNA topoisomerase II in the parental and in the resistant cell lines. Alternating the usage of CPT and VP-16 for the treatment of cancer is indicated.
引用
收藏
页码:2443 / 2452
页数:10
相关论文
共 45 条
  • [1] CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I
    ANDOH, T
    ISHII, K
    SUZUKI, Y
    IKEGAMI, Y
    KUSUNOKI, Y
    TAKEMOTO, Y
    OKADA, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) : 5565 - 5569
  • [2] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [3] CARMICHAEL J, 1987, CANCER RES, V47, P936
  • [4] CHANG JY, 1991, CANCER RES, V51, P1755
  • [5] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [6] DEBENHAM PG, 1988, MUTAT RES, V199, P1
  • [7] DEFFIE AM, 1989, CANCER RES, V49, P58
  • [8] DREWINKO B, 1974, CANCER RES, V34, P747
  • [9] ENG WK, 1990, MOL PHARMACOL, V38, P471
  • [10] FERGUSON PJ, 1988, CANCER RES, V48, P5956